Author

Heribert Arnhof

Boehringer Ingelheim (Austria)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Assay:imaging· 1 Assay:metabolomics· 1 Organism:mouse· 1 Research Focus:perturbation response prediction· 1 Assay:proteomics· 1

Frequent Co-Authors

Andrea Olarte-San JuaniD· 1 shared Barbara MairiD· 1 shared Chiara AmbrogioiD· 1 shared Enrico PatruccoiD· 1 shared Esther CastellanoiD· 1 shared Ettore PetriniiD· 1 shared Eugenio SantosiD· 1 shared Fernando C. BaltanásiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Andrea Olarte-San JuanORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Pharmacological SOS1 inhibitor BI-3406 demonstrates in vivo anti-tumor activity comparable to SOS1 genetic ablation in KRAS mutant tumors

Fernando C. Baltanás, Maximilian Kramer‐Drauberg, Rósula García‐Navas, Enrico Patrucco, Ettore Petrini, Heribert Arnhof, Andrea Olarte-San Juan, Pablo Rodríguez-Ramos, Javier Borrajo-Sánchez, Nuria Calzada, Esther Castellano, Barbara Mair, Kaja Kostyrko, Marco H. Hofmann, Chiara Ambrogio, Eugenio Santos

This study shows that the SOS1 inhibitor BI-3406 effectively reduces tumor growth in KRAS mutant cancers, similar to genetic SOS1 ablation, with comparable efficacy to another KRAS inhibitor.

Proceedings of the National Academy of Sciences · Mar 12, 2025Peer-reviewedCancer Biology